Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.47), $0.01 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley Resumes Global Payments (GPN) at Equalweight
• Accenture downgraded by TD Cowen on AI concerns